Log in

Covetrus Stock Price, News & Analysis (NASDAQ:CVET)

$9.46
-0.66 (-6.52 %)
(As of 10/23/2019 02:02 AM ET)
Today's Range
$8.16
Now: $9.46
$10.02
50-Day Range
$9.49
MA: $12.08
$14.70
52-Week Range
$8.16
Now: $9.46
$43.83
Volume8.30 million shs
Average Volume1.67 million shs
Market Capitalization$1.06 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:CVET
CUSIPN/A
CIKN/A
Phone888-280-2221

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.78 billion

Profitability

Miscellaneous

Employees5,000
Market Cap$1.06 billion
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for CVET and its competitors with MarketBeat's FREE daily newsletter.


Covetrus (NASDAQ:CVET) Frequently Asked Questions

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

How were Covetrus' earnings last quarter?

Covetrus Inc (NASDAQ:CVET) released its quarterly earnings results on Tuesday, August, 13th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.16 by $0.04. The business earned $1.01 billion during the quarter, compared to the consensus estimate of $1.05 billion. View Covetrus' Earnings History.

When is Covetrus' next earnings date?

Covetrus is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Covetrus.

What price target have analysts set for CVET?

8 equities research analysts have issued 12-month price targets for Covetrus' stock. Their forecasts range from $11.00 to $21.00. On average, they expect Covetrus' share price to reach $15.25 in the next twelve months. This suggests a possible upside of 61.2% from the stock's current price. View Analyst Price Targets for Covetrus.

What is the consensus analysts' recommendation for Covetrus?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Covetrus.

Has Covetrus been receiving favorable news coverage?

Media headlines about CVET stock have been trending somewhat negative on Wednesday, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Covetrus earned a coverage optimism score of -1.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Covetrus.

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include IDEXX Laboratories (IDXX), Alphabet (GOOG), Kraft Heinz (KHC), Evolent Health (EVH), Nokia Oyj (NOK), Koninklijke DSM (DSM), LVMH Moet Hennessy Louis Vuitton (MC), Aimmune Therapeutics (AIMT), Baidu (BIDU) and Cognex (CGNX).

Who are Covetrus' key executives?

Covetrus' management team includes the folowing people:
  • Benjamin J. Shaw, President, Chief Executive Officer & Director
  • Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
  • Matthew Leonard, Executive VP & President-North America
  • Jim Young, Chief Human Resources Officer & Senior VP
  • Erin Powers Brennan, Secretary, Senior Vice President & General Counsel

Who are Covetrus' major shareholders?

Covetrus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Alecta Pensionsforsakring Omsesidigt (0.56%), CWM LLC (0.15%), Fenimore Asset Management Inc. (0.04%), Pacer Advisors Inc. (0.03%), State of Michigan Retirement System (0.03%) and Country Club Trust Company n.a. (0.02%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Erin Powers Brennan and Timothy Ludlow. View Institutional Ownership Trends for Covetrus.

Which major investors are buying Covetrus stock?

CVET stock was purchased by a variety of institutional investors in the last quarter, including Alecta Pensionsforsakring Omsesidigt, CWM LLC, Fenimore Asset Management Inc., Pacer Advisors Inc., State of Michigan Retirement System, Country Club Trust Company n.a., Bridge Creek Capital Management LLC and Virginia Retirement Systems ET AL. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw and Erin Powers Brennan. View Insider Buying and Selling for Covetrus.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $9.46.

How big of a company is Covetrus?

Covetrus has a market capitalization of $1.06 billion and generates $3.78 billion in revenue each year. Covetrus employs 5,000 workers across the globe.View Additional Information About Covetrus.

What is Covetrus' official website?

The official website for Covetrus is http://www.henryscheinvet.com/.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]


MarketBeat Community Rating for Covetrus (NASDAQ CVET)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  149
MarketBeat's community ratings are surveys of what our community members think about Covetrus and other stocks. Vote "Outperform" if you believe CVET will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVET will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: Stocks Increasing Dividends

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel